ArticleReproductive toxicology (Elmsford, N.Y.)2026
Per- and polyfluoroalkyl substances (PFAS) and menstrual cycle characteristics in midlife women: The Study of Women's Health Across the Nation.
Article in Reproductive toxicology (Elmsford, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveEvidence suggests exposure to endocrine-disrupting chemicals, including per- and polyfluoroalkyl substances (PFAS), may disrupt ovarian function and influence menstrual bleeding. PFAS have been associated with reproductive aging; however, longitudinal data on PFAS and menstrual cycle characteristics (cycle length, bleeding patterns) are limited.
methodsWe examined 952 women aged 45-55 years from the Study of Women's Health Across the Nation, with seven PFAS concentrations measured in serum collected in 1999-2000. Menstrual cycle data were collected prospectively using monthly calendars for two years following PFAS measurement. Menstrual cycle length (MCL) was evaluated using linear quantile mixed models at the 25th, 50th, 75th, and 90th percentiles. Bleed length and binary bleeding outcomes (long and heavy) were analyzed using linear and generalized linear mixed models. Models were adjusted for race/ethnicity, education, physical activity, menopause status, smoking status, body mass index, and baseline menstrual characteristics.
resultsHigher perfluorooctane sulfonic acid concentrations were associated with shorter short cycles (MCL at the 25th percentile) (-0.52 days; 95% CI, -1.09-0.05) and longer long cycles (MCL at the 90th percentile) (2.77 days; 95% CI, 1.96-3.58). Perfluorononanoic acid was associated with longer short cycles (0.56 days; 95% CI, 0.06-1.05). No PFAS was associated with median MCL. Most PFAS, except 2-(N-methyl-perfluorooctane sulfonamido) acetic acid and 2-(N-ethyl-perfluorooctane sulfonamido) acetic acid, were associated with shorter menses and lower odds of long or heavy bleeding.
conclusionPFAS exposure may be associated with increased menstrual cycle variability and reduced bleeding. Further research in younger cohorts is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.